188例氯氮平换用维思通治疗分裂症临床研究  

Clinical Study of Risperidone in place of Clozapine in 188 Schizophrenias

作　　者：于丽慧 王曙光 

机构地区：[1]中国．内蒙古赤峰市安定医院,024006

出　　处：《国际中华神经精神医学杂志》2005年第3期182-184,共3页

摘　　要：为探讨氯氮平换用维思通治疗分裂症的可行性、有效性及安全性，找出能在临床中推广的规律，选择符合CCMD-Ⅲ精神分裂症诊断标准，既往采用氯氮平治疗的患者共188例，系统换用维思通治疗16周进行观察，在治疗中及治疗前后以BPRS和TESS量表评定疗效和副作用。结果有效率86％、显效率66％、恶化4％，BPRS总分及因子分治疗前后均有极显着性差异（P〈0.001）。常见的副作用为EPS（23％）及失眠（15%），以安坦及苯二氮（艹卓）革类药处理有效，其它副作用不多见，副作用与维思通剂量有关，提示，氯氮平换用维思通治疗精神分裂症可行、有效且较安全。To inquire into the practicability, availability and secruity of risperidone in place of clozapine,and discover the law of clinical populization, 188 schizophrenics （CCMD-Ⅲ） who pastly took clozapine were selected and systematically replaced by risperidone for 16 weeks. During treatment and at pre-and post-treatment, the curative effect and side effect were evaluated with BPRS and TESS. ResultThe effective rate was 86%, effectual 66% and deteriorative 4%, there were much signifi- cant difference in both the BPRS total and factor scores between pre-and post-treatment （P〈0. 001）, Common side effects were EPS （23%） and insomnia （15 %）which responded to artane and henzodiazepine, other side effects were rare. The side effects were related to the dosage of risperidone. These suggests risperidone in place of clozapine is practical, available and safe.

关 键 词：维思通 氯氮平 换用 精神分裂症 维思通治疗 氯氮平治疗 临床研究 CCMD-Ⅲ BPRS 治疗前后 

分 类 号：R749.305[医药卫生—神经病学与精神病学] R749.3[医药卫生—临床医学]